Research programme: olfactory epithelium stem cell therapy - RhinoCyte
Latest Information Update: 20 Jul 2016
At a glance
- Originator RhinoCyte
- Class Stem cell therapies
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neurodegenerative disorders; Spinal cord injuries
Most Recent Events
- 20 Jul 2016 Preclinical development is ongoing for Spinal cord injuries and Neurodegenerative disorders in USA